SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Adverum Biotechnologies to Participate in Upcoming Conferences
[March 18, 2019]

Adverum Biotechnologies to Participate in Upcoming Conferences


MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the Company’s participation in several upcoming conferences:

Event: Chardan’s In Vivo Gene Therapy and Gene Editing Summit
Panel Title: Gene Therapy and Gene Editing to the Retina
Panel Participant: Mehdi Gasmi, Ph.D., president and chief scientific officer, Adverum Biotechnologies
Date: Monday, March 18, 2019
Time: 5:05 – 6:05 pm ET
Location: Miami, Florida

Event: Retina World Congress Unplugged
Panel Title: Cell and Gene Therapy
Panel Moderator: Pravin Dugel, M.D., managing partner of Retinal Consultants of Arizona and clinical professor at the Department of Ophthalmology at the Keck School of Medicine, University of Southern California
Panel Participant: Mehdi Gasmi, Ph.D., presidentand chief scientific officer, Adverum Biotechnologies



Date: Thursday, March 21, 2019
Time: 10:07 – 10:34 am ET
Location: Fort Lauderdale, FL

Event:  2019 Cell & Gene Meeting on the Mediterranean
Presentation by: Mehdi Gasmi, Ph.D., president and chief scientific officer, Adverum Biotechnologies
Date:   April 22 – 24, 2019
Time:   1:35 pm CET
Location: Hotel Arts Barcelona, Marina 19-21, 08005 Barcelona, Spain
Webcast: http://www.meetingonthemed.com/webcast


About Adverum Biotechnologies, Inc.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. As a leader in ophthalmic gene therapy, Adverum has collaboration agreements with Regeneron Pharmaceuticals and Editas Medicine. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.

Investor and Media Inquiries: 
Amy Figueroa, CFA
Investor Relations Consultant
afigueroa@adverum.com
650-823-2704

ADVERUM_ID_RGB 200x49.jpg


[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2019 Technology Marketing Corporation. All rights reserved | Privacy Policy